Oracle Runs

Oracle findings and outcome history for A Study of IBI363 in Subjects with Advanced Solid Malignancies (NCT06281678).

Runs

Findings

Latest Run

Apr 6, 2026, 2:57 PM

All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed85% confidenceGrok 4.20 (xAI)

Will the results be positive?

NCT06281678 (US Phase 2 basket in melanoma/NSCLC/CRC/RCC) remains recruiting with primary completion in 2026. No public efficacy readout or ORR interpretation found for this exact trial. Available data are from separate Phase 1 studies showing encouraging signals in related indications.

Found Apr 6, 2026, 2:09 PMReviewed Apr 6, 2026, 2:25 PM

Web Searchclinicaltrials.gov

NCT06281678 | A Study of IBI363 in Subjects with Advanced Solid Malignancies

Phase 2 open-label multicenter study evaluating efficacy/safety of IBI363 in advanced refractory solid malignancies including melanoma, NSCLC, CRC, RCC. Recruiting; estimated primary completion 2026-03-01. Primary endpoint ORR.

Web Searchprnewswire.comJun 1, 2024, 12:00 AM

Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363

Phase 1 data: ORR 28.1% in melanoma (32% in IO-treated subset), ORR 12.7% in CRC. Not specific to NCT06281678 Phase 2.

NO_DECISIONDismissed90% confidencemanual-chat-review

Will the results be positive?

ClinicalTrials.gov still lists this study as recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:32 PM

ClinicalTrialsclinicaltrials.govDec 19, 2024, 12:00 AM

Study Details | NCT06281678 | ClinicalTrials.gov

ClinicalTrials.gov lists recruiting; primary completion 2026-03-01; hasResults=false on the latest posted update.

NO_DECISIONDismissed94% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific Phase 2 readout was found for NCT06281678. The registry still shows the study as recruiting/ongoing, and Innovent’s 2024 annual results describe IBI363 Phase 1/2 work as underway with future result updates rather than reporting an outcome for this exact trial.

Found Apr 1, 2026, 7:16 PMReviewed Apr 1, 2026, 7:16 PM

ClinicalTrialsclinicaltrials.gov

Study Details | NCT06281678 | A Study of IBI363 in Subjects with Advanced Solid Malignancies | ClinicalTrials.gov

ClinicalTrials.gov lists NCT06281678 as a Phase 2 study of IBI363 in advanced solid malignancies; the trial remains recruiting/ongoing rather than reported out.

Sponsorinvestor.innoventbio.comMar 26, 2025, 12:00 AM

Innovent Biologics 2024 Annual Results Announcement

Innovent says multiple IBI363 Phase 1 and Phase 2 studies are underway and that it will continue to update IBI363 study results in 2025, indicating no clear public outcome for NCT06281678 yet.

Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.